## **DEPARTMENT OF HEALTH & HUMAN SERVICES**



Food and Drug Administration 2098 Gaither Road Rockville MD 20850

## FEB 1 2000

Cogent Diagnostics LTD c/o Mr. Randy Wilson Hycor Biomedical Inc. 7272 Chapman Avenue Garden Grove, California 92841

Re: K993085

Trade Name: Autostat™II ACA Screen ELISA

Regulatory Class: II Product Code: MID

Dated: November 19, 1999 Received: November 26, 1999

## Dear Mr. Wilson:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven I. Gutman, M.D., M.B.A.

Director

Division of Clinical Laboratory Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Steven Butman

Enclosure

	Pageof
510(k) Number (if known): \$\frac{493085}{}\$	<b>,</b> )
510(k) Number (if known): K993085  Device Name: Autostar Aca Sce	efy SIISA
	<del></del>
Indica	ations for Use.
Enzyme linked immunosorbent assay  IgA autoantibodies to cardiolipin in l	method for the detection of IgG, IgM and human serum.
Uses:	
autoimmune diseases associated with including anti-phospholipid syndrom	say can be used as an aid in the diagnosis of n elevated levels of anti-cardiolipin antibodies e.  ne indicator in a multi-factorial diagnostic
The assay may be used on the Hycor	Hy•Tec Automated EIA instrument.
For in vitro diagnostic use only.	
(PLEASE DO NOT WRITE BELOW THIS LIN	E-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)	
1	(Division Sign-Off) Division of Clinical Laboratory Devices K993085
Prescription Use \( \sum_{\text{CFR 801 109}} \)	OR Over-The-Counter Use

(Optional Format 1-2-96)